Fenofibrate Reduces C-Reactive Protein Levels in Hypertriglyceridemic Patients With High Risks for Cardiovascular Diseases.
10.4070/kcj.2012.42.11.741
- Author:
Yun Joo MIN
1
;
Young Hwan CHOI
;
Cheol Won HYEON
;
Jun Hwan CHO
;
Kyung Joon KIM
;
Jee Eun KWON
;
Eun Young KIM
;
Wang Soo LEE
;
Kwang Je LEE
;
Sang Wook KIM
;
Tae Ho KIM
;
Chee Jeong KIM
Author Information
1. Division of Cardiology, Department of Internal Medicine, College of Medicine, Chung-Ang University, Seoul, Korea. cjkim@cau.ac.kr
- Publication Type:Original Article
- Keywords:
Fenofibric acid;
C-reactive protein;
Lipids;
Lipoprotein
- MeSH:
Body Mass Index;
C-Reactive Protein;
Cardiovascular Diseases;
Case-Control Studies;
Fenofibrate;
Humans;
Lipoproteins;
Overweight
- From:Korean Circulation Journal
2012;42(11):741-746
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES: The effects of fenofibrate on C-reactive protein (CRP) are under debate. We investigated the effect of fenofibrate on CRP levels and the variables determining changes. SUBJECTS AND METHODS: This case-control study enrolled 280 hypertriglyceridemic patients who were managed either with 200 mg of fenofibrate (Fenofibrate group, n=140) or with standard treatment (comparison group, n=140). CRP levels were measured before and after management for 2 months. RESULTS: CRP levels decreased in both the fenofibrate (p=0.003) and comparison (p=0.048) groups. Changes in CRP levels were not significantly different between the two groups (p=0.27) and were negatively associated with baseline CRP levels (r=-0.47, p<0.001). In patients with a baseline CRP level > or =1 mg/L, CRP levels also decreased in both groups (p=0.000 and p=0.001 respectively), however, more in the fenofibrate group than in the comparison group (p=0.025). The reduction of CRP was associated with higher baseline CRP levels (r=-0.29, p=0.001), lower body mass index (BMI, r=0.23, p=0.007), and fenofibrate therapy (r=0.19, p=0.025). CRP levels decreased more in the fenofibrate group than in the comparison group in patients with a BMI < or =26 kg/m2 with borderline significance (-1.21+/-1.82 mg/L vs. -0.89+/-1.92 mg/L, p=0.097). In patients with a high density lipoprotein-cholesterol level <40 mg/dL, CRP levels were reduced only in the fenofibrate group (p=0.006). CONCLUSION: Fenofibrate reduced CRP levels in hypertriglyceridemic patients with high CRP and/or low high density lipoprotein-cholesterol levels and without severe overweight. This finding suggests that fenofibrate may have an anti-inflammatory effect in selected patients.
